Abstract
Androgen deprivation therapy (ADT), a treatment for prostate cancer, is associated with bone loss and fractures. Dual energy x-ray absorptiometry (DXA) measured bone mineral density does not assess vertebral fractures (VF). High resolution microMRI (HR-MRI) assesses bone microarchitecture and provides structural information.
To determine if VF identification increased the diagnosis of osteoporosis beyond DXA and if HR-MRI demonstrated skeletal deterioration in men with VF, we cross-sectionally studied 137 men ≥ 60 years with nonmetastatic prostate cancer on ADT for ≥6 months. Vertebral fracture assessment (VFA) by DXA was confirmed with x-rays. HR-MRI of the wrist included bone volume to total volume (BV/TV), surface density (trabecular plates), surface/curve ratio (plates/rods) and erosion index (higher depicts deterioration).
VF were found in 37% of men; the majority were unknown. 7% of participants were classified as osteoporotic by hip or spine DXA. 37% of men without osteoporosis by DXA had VF identified, suggesting that 90% of patients with clinical osteoporosis would have been misclassified by DXA alone. By ANOVA comparison across VF grades, the BV/TV, surface density and spine, hip and wrist DXA were lower, and erosion index was higher in men with moderate-severe VF compared to lesser grades (all p<0.05). By unadjusted ROC analysis, the addition of HR-MRI to DXA at the spine, hip and femoral neck, added substantially (AUC increased 0.831 to 0.902, p<0.05) to prediction of moderate-severe vertebral fracture. HR-MRI indices were associated with spine, hip and wrist DXA measures (p< 0.01). Longer duration of ADT was associated with lower BV/TV, surface density and surface/curve ratio (p<0.05).
ADT for men with prostate cancer is associated with silent VF. DXA alone leads to misclassifications of osteoporosis which can be avoided by VF assessment. HR-MRI provides a novel technique to assess deterioration of structural integrity in men with VF and adds microstructural information.
Keywords: prostate cancer, osteoporosis, bone densitometry, radiology
INTRODUCTION
Prostate cancer is the second leading cause of cancer related death in men and is the most common visceral malignancy 1. Androgen deprivation therapy (ADT), a common treatment for metastatic and nonmetastatic prostate cancer, has increased four-fold over the past decade 2;3. However, androgen deprivation therapy also increases fracture risk two-to-four fold 4–8. The resulting hip fractures carry an increased mortality up to 30% in men and vertebral fractures are also associated with increased mortality and decreased quality of life 9;10. Therefore it is important to identify men who are at greatest risk for fractures.
The gold standard to determine fracture risk is bone mineral density assessed by dual-energy x-ray absorptiometry (DXA). However, bone mineral density only explains about 60% of fracture risk in untreated patients 11–13. We have previously shown that conventional DXA criteria for osteoporosis results in a misdiagnosis of over 75% of men with prostate cancer on androgen deprivation therapy 14. However, other factors such as trabecular microstructure contribute significantly to bone strength and determine fracture risk.
Until relatively recently, bone microarchitecture could not be assessed except by iliac crest bone biopsy. Several recent techniques by CT or MRI can examine trabecular bone microstructure 15–18. A technique known as high resolution MRI (HR-MRI) of the radius provides a three-dimensional image of bone trabecular microarchitecture 16–18. HR-MRI examines topographical microarchitecture of the radius and examines ratios of plate-like to rodlike trabecular structure. We have previously reported that in postmenopausal women receiving a bisphoshonate, risedronate, over 12 months, trabecular microarchitecture with HR-MRI of the wrist demonstrated improvements in trabecular microstructure which were not appreciated by conventional bone mineral density by DXA 19. The goals of our study were to examine the cross-sectional association of HR-MRI topographical parameters with fragility fractures, conventional bone density and biochemical markers of bone turnover in this cohort of men with prostate cancer on androgen deprivation therapy.
MATERIALS AND METHODS
Design and Subjects
This cross-sectional study included 137 men age 60 and older with nonmetastatic prostate cancer on ADT for ≥ 6 months. Participants were enrolled from urology and geriatric practices and advertisements. ADT included orchiectomy or gonadatropin releasing hormone agonists with or without antiandrogens. Men were excluded if they had metastatic prostate cancer, nonmetstatic prostate cancer with a prostate specific antigen (PSA) level >4 (unless therapeutic adjustments were being made), if they were currently on medications known to alter bone mineral metabolism within the past year (including bisphosphonate, corticosteroids, antiseizure medicines or other antiresorptive therapy) or if they had diseases known to affect osteoporosis (for example hyperparathyroidism, thyrotoxicosis). The Institutional Review Board at the University of Pittsburgh approved the study, and participants provided written informed consent.
Measures
Clinical Characteristics
Participants completed a food frequency questionnaire to evaluate their total calcium and vitamin D intake from diet and vitamin supplements. Participants also completed a questionnaire regarding family history, medical, surgical and fracture histories in addition to information on medication, activity level, tobacco and alcohol use. Height was obtained with a Harpenden stadiometer (Holtain Ltd-Crymych, Dyfed, UK). Weight was measured with a Health-O-Meter balance-beam scale (Sunbeam, Inc, Boca Raton, FL). Body mass index (BMI) was calculated as weight/(height)2 in kg/m2. Patients were asked to report their tallest height from memory and height loss was calculated from the tallest height and current height.
Bone Mineral Density
Bone mineral density of the PA spine (L1-L4), hip (total hip, femoral neck), right radius (1/3 distal radius, ultra distal radius and total radius) was performed by dual energy x-ray absorptiometry (DXA) using a Hologic Discovery A (Hologic Inc, Bedford, MA). We analyzed absolute bone mineral density in g/cm2 and calculated T-scores (number of standard deviation units from adult peak bone mass) using the Hologic male database. We used World Health Organization criteria to define osteoporosis (T-score ≤ −2.5 SD), low bone mass (T-score between −2.5 and 1.0 SD) and normal (T-score ≥ −1.0 SD) 20. The coefficient of variation for our DXA machine is 1.3% for the spine and 1.4% for the total hip 21.
Fracture Assessment
We assessed vertebral fractures utilizing Vertebral Fracture Assessment (VFA) performed with lateral spine imaging (T5-L4) on the Hologic Discovery A using the manufacturer’s standard protocols. We classified vertebral fractures based on reduction in vertebral height according to the Genant semi-quantitative method analysis 22. Fractures were classified as grade 1 (mild) with a 20–25% loss of vertebral height, grade 2 (moderate) with 25–40% loss of vertebral height or grade 3 (severe) with >40% loss of vertebral height. In addition, all fractures were confirmed by conventional lateral, thoracic and lumbar x-rays. These were graded by a single radiologist. We have previously reported that sensitivity and specificity of VFA versus semi-quantitative radiography were 100% and 95%, respectively. The Kappa statistic for agreement was 0.92 14 Participants were categorized as having a moderate-severe, mild or no vertebral fracture based on their most severe reading in T5-L4 locations.
FRAX
The fracture risk assessment algorithm was used to calculate the 10 year risk of an osteoporotic fracture and risk of hip fracture 23 using the femoral neck BMD (g/cm2) for each participant.
High Resolution Magnetic Resonance Imaging
High resolution magnetic resonance imaging (HR-MRI) uses an algorithm that transforms data into a detailed three-dimensional model of bone microstructure as previously described 19;24. Subjects had a coil placed on their right distal forearm. They were then scanned with a GE Signa 1.5 Tesla scanner (General Electric Medical Systems, Waukesha, WI, USA). The technique quantifies the degree to which trabecular plates (surfaces) have deteriorated to become rods (curves), a change that is characteristic of osteoporosis 17. Using the patented unique algorithm, each image voxel can be classified as belonging to a surface or curve junction between two topographical types. An erosion index (EI) is determined that represents the ratio of voxels expected to decrease during resorptive bone loss derived by those that are expected to increase. The topographical parameters (plate-to-rod ratio, an erosion index) are computed after resolution has been enhanced by the software, resulting in a voxel size of approximately 67 μm isotropic. The software places the region of interest automatically. The outer boundary of the region of interest is typically within 1 mm of the cortical endostial boundary. The user may manually modify the region of interest, if needed. The indices include: the bone volume to total volume ratio (BV/TV), topographical surface density (Surface Density), topographical curve density (Curve Density), surface to curve ratio (Surf/Curv where higher values indicate a more intact trabecular network and lower values indicate a network that has deteriorated) and an erosion index (EI- a ratio of parameters expected to increase when bone trabeculae deteriorates with higher values indicating greater deterioration). The coefficient of variation for HR-MRI parameters is 4 – 7% and the reliability expressed is the interclass correlation coefficient are 0.95 – 0.97 at the radius 25.
Bone Mineral Metabolism and Turnover Markers
Serum 25-hydroxyvitamin D was assessed by liquid chromatography/mass spectrometry. Parathyroid hormone was measured by Elisa (ALPCO Diagnostics, Salem, NH), Collagen type 1 cross-linked c-telopeptide (CTx), a marker of bone resorption, was assayed by Elisa (Crosslaps, Immunodiagnostics Systems Inc, Scottsdale, AZ) and the marker of bone formation, procollagen type 1 amino-terminal propeptide (P1NP) was assessed by radioimmune assay (Immunodiagnostics Systems Inc, Scottsdale, AZ).
Statistical Analysis
SAS® Version 9.2 (SAS Institute Inc, Cary, NC) was used for all statistical analyses. We used appropriate descriptive statistics and graphical methods to summarize the participant characteristics and outcomes of bone health across the three categories of participants defined by their vertebral fracture status (none/mild/moderate-severe). All DXA- and MRI-derived measured were used as continuous variables in all analyses to ensure maximum amount of information from the measures are used in eliciting results. We used analysis of variance (ANOVA) with pairwise comparisons using Fisher’s least significant difference to make comparisons of outcomes and clinical characteristics across the three vertebral fracture status categories. We used multiple coefficient of determination (R2) from ANOVA models as a measure of overall strength of association between vertebral fractures and each outcome/clinical characteristic. We used Pearson product-moment correlation coefficients (r) to examine association between traditional BMD measures and HR-MRI measures as well as duration of ADT. Finally, we used multivariable logistic regression models to evaluate whether HR-MRI measures add substantially to the accuracy of predicting moderate-severe VFs above and beyond the combination of commonly used DXA-derived t-scores for spine, hip and femoral neck using the unadjusted area under receiver operator characteristic curve (c-statistic or AUC) where an increase of 0.025 or greater is considered substantial 26. Specifically, using only those participants with both DXA- and MRI-derived measures, we first computed AUC for DXA-derived measures alone, and then for both DXA- and MRI-derived measures together. The increase in AUC was interpreted as being due to additional information contained in MRI-derived measures above and beyond that contained in DXA-derived measures.
RESULTS
Two hundred seventeen men were telephone screened and 160 were eligible. One hundred thirty-seven were enrolled. HR-MRI was performed in 108 men. Of the 137 men enrolled, 86 had no vertebral fracture and 41 had a mild vertebral fracture and 10 had a moderate to severe vertebral fracture. Of the 51 men with vertebral fractures, 48 (94.1%) men had silent fractures that they were unaware of and 23 (45.1%) had 2 or more vertebral fractures.
The average daily calcium intake, including diet plus supplementation, ranged from 1228 ± 65 to 1769 ± 163 mg/d (mean ± standard error) across the three vertebral fracture categories and was higher in those with moderate-severe VF (Table 1). There was no significant difference in age, body mass index, vitamin D intake, duration of androgen deprivation therapy or PSA between men with and without vertebral fractures. Height loss was greater in men with moderate-severe VF compared to men with no or mild VF (both p<0.05, Table 1).
TABLE 1.
Clinical Characteristics, Bone Turnover Markers and Bone Mineral Density T-Scores in Men Across Grades of Fracture
| No Vertebral Fracture (N=86) |
Mild Vertebral Fracture (N=41) |
Mod-Severe Vertebral Fracture (N=10) |
|
|---|---|---|---|
| Age (years) | 73.5 ± 0.8 | 74.2 ± 1.1 | 79.7 ± 2.1 |
| BMI (kg/m2) | 29.6 ± 0.4 | 29.7 ± 0.8 | 28.7 ± 1.4 |
| Height loss (cm)* | 3.6 ± 0.3 | 4.2 ± 0.4 | 7.0 ± 1.7 |
| Duration ADT (months) | 36.8 ± 5.1 | 40.1 ± 6.9 | 63.2 ± 20.2 |
| PSA (ng/mL) | 2.0 ± 0.5 | 4.4 ± 2.5 | 1.5 ± 0.5 |
| Calcium intake (mg/d)†* | 1228 ± 65 | 1394 ± 105 | 1769 ± 163 |
| Vitamin D intake (IU/d)† | 749 ± 60 | 1074 ± 217 | 1017 ± 244 |
| Calcium (mg/dL) | 9.6 ± 0.0 | 9.6 ± 0.1 | 9.6 ± 0.2 |
| 25-hydroxyvitamin D (mg/dL) | 34.4 ± 1.2 | 33.4 ± 1.8 | 35.9 ± 3.4 |
| PTH (pg/mL)# | 55.9 ± 2.5 | 50.3 ± 2.7 | 66.5 ± 10.0 |
| P1NP(ug/L) | 53.7 ± 4.0 | 57.5 ± 7.6 | 63.5 ± 7.5 |
| CTx (ng/mL)# | 0.54 ± 0.04 | 0.53 ± 0.04 | 0.80 ± 0.16 |
| BMD T-score (SD) | |||
| PA spine# | 0.21 ± 0.17 | 0.26 ± 0.29 | −1.13 ± 0.59 |
| Total hip# | −0.58 ± 0.09 | −0.54 ± 0.14 | −1.22 ± 0.31 |
| Femoral Neck* | −1.17 ± 0.09 | −1.27 ± 0.15 | −1.93 ± 0.28 |
| 1/3 Distal radius* | −1.47 ± 0.17 | −1.05 ± 0.25 | −2.79± 0.81 |
| FRAX 10 Year risk of fracture | |||
| Major osteoporotic fracture (%)* | 7.1 ± 0.3 | 7.6 ± 0.5 | 9.9 ± 1.3 |
| Hip fracture (%) # | 1.8±0.2 | 2.0 ± 0.2 | 3.8 ± 0.7 |
| HR-MRI | |||
| BV/TV (%) * | 12.9 ± 0.3 | 13.0 ± 0.3 | 11.0 ± 0.5 |
| Surface Density * | 0.062 ± 0.001 | 0.063 ± 0.002 | 0.050 ± 0.003 |
| Surface/Curve # | 11.1 ± 0.5 | 11.2 ± 0.6 | 7.8 ± 0.9 |
| Erosion Index * | 0.88 ± 0.03 | 0.86 ± 0.03 | 1.07 ± 0.07 |
Results as mean ± standard error,
p<0.05,
p<0.1, ANOVA across VF grades,
total dietary and supplement
Serum calcium and 25-hydroxyvitamin D were similar across the 3 groups (Table 1). However, serum PTH trended higher in men with moderate-severe VF compared to those with mild VF (p<0.05). In addition CTx tended to be higher in men with moderate-severe VF compared to those with no or mild VF (both p<0.05). The multiple coefficient of determination for the ANOVA models for MRI indices was also weak and ranged from R2=0.05 to 0.09.
Seven percent or 10/137 of the participants were classified as having osteoporosis by conventional bone mineral density of the spine, total hip or femoral neck. Thirty-seven percent or 47 of the remaining 127 men without osteoporosis by bone mineral density (men who had normal to low bone mass) had a vertebral fracture identified by VFA and conventional x-rays. This suggests that 89.5% or 51 of the 57 patients with clinically defined osteoporosis would have been misclassified by bone mineral density alone. However if we classified osteoporosis by bone mineral density of the spine, total hip, femoral neck or 1/3 distal radius, 27% of men would have been characterized as osteoporotic.
By ANOVA comparison across VF grades, bone mineral density was lower at the PA spine, total hip, femoral neck and 1/3 distal radius in men with moderate-severe VF compared to lesser grades (all p<0.05, Fig 1). Similar trends were noted for T-scores (Table 1). The multiple coefficient of determination for the ANOVA models for BMD was weak and ranged from R2=0.04 to 0.06. The FRAX score for the 10 year risk of a major osteoporotic fracture or a hip fracture was higher in men with moderate-severe VF compared to lesser grades (p<0.05, Table 1).
Figure 1.

Conventional bone mineral density assessed by DXA at the PA spine, total hip, femoral neck and 1/3 distal radius in men with no, mild or moderate-severe vertebral fractures. Results as mean ± standard error.
*p<0.05 comparison across VF groups using ANOVA
The BV/TV was lower, surface density was lower and erosion index was higher in men with moderate to severe VF compared to lesser grades (all <0.05, Fig 2) by ANOVA comparison across VF grades. In addition, BV/TV ratio was higher, surface density was higher, the surface/curve ratio was higher and erosion index was lower in men with moderate-severe VF compared to none (all p<0.05) or those with mild VF (all p<0.05, Fig 2). The multiple coefficient of determination for the ANOVA models for MRI indices was also weak and ranged from R2= 0.05 to 0.09.
Figure 2.

Indices of HR-MRI including BV/TV (%), surface density (surface), surface/curve ratio (surface/curve) and erosion index in men with no, mild or moderate-severe vertebral fractures. Results as mean ± standard error.
*p<0.05, # p<0.1 comparison across VF grades using ANOVA. Surface density × 10−2, Erosion index × 10−1
We examined the unadjusted area under the receiver operator curve (AUC) for predicting a moderate-severe VF or any VF. Information contained in all MRI measures added substantially and significantly to that contained in the hip and spine T-scores. AUC for hip and spine t-scores was 0.804, which increased to 0.890 when hip and spine t-scores were considered together with MRI measures, showing a substantial increase of 0.086 (p=0.0401) due to the information contained in MRI measures above and beyond that contained in hip and spine t-scores. Similarly, the total hip, femoral neck, spine T-scores had an AUC of 0.831 which increased to 0.902 when considered together with the MRI measures for the prediction of moderate-severe VF, resulting in a substantial increase of 0.071 (p=0.0471). The addition of MRI measures to the total hip, femoral neck, spine and 1/3 distal radius added substantially (AUC increased 0.829 to 0.902 by 0.073) to the prediction of moderate-severe VF, but this was not statistically significant (p=0.1002). The addition of the MRI measures added substantially to the prediction for all VF (includes mild, moderate-severe VF) as measured by the increase in AUC magnitude (≥0.025), but was not statistically significant.
BMD at the ultradistal radius was moderately positively associated with BV/TV ratio (r=0.65), surface density (r=0.62), surface/curve ratio (r=0.58) and negatively associated with erosion index (r=−0.46, all p<0.0001, Table 2). The positive associations at other sites were weaker and ranged from r=0.29 to 0.39 at the spine, r=0.46 to 0.50 at the total hip and r=0.45 to 0.49 at the femoral neck (all p<0.05). The indices of HR-MRI were not associated with vitamin D, PTH or bone turnover markers. Duration of ADT was weakly and negatively associated with HR-MRI (r ranged from −0.23 to −0.27, p<0.05) and 1/3 distal radius (r=−0.21, p<0.05) but not at the spine or hip sites.
Table 2.
Correlations of Bone Mineral Density and Indices of HR-MRI
| Spine BMD | Hip BMD | Femoral Neck BMD | Ultra Distal Radius BMD | 1/3 Distal Radius BMD | Duration on ADT | |
|---|---|---|---|---|---|---|
| BV/TV (%) | 0.37** | 0.50** | 0.49** | 0.65** | 0.44** | −0.24* |
| Surface Density | 0.39** | 0.50** | 0.48** | 0.62** | 0.42** | −0.27* |
| Surface/Curve | 0.29** | 0.46** | 0.45** | 0.58** | 0.46** | −0.23* |
| Erosion Index | −0.25* | −0.37** | −0.36** | −0.46** | −0.38** | 0.21 |
| Duration on ADT | −0.12 | −0.08 | −0.11 | −0.15 | −0.21* | ___ |
p<0.05,
p<0.01
HR-MRI scans of 2 representative patients are shown in Figure 3. Although the spine and hip T-scores were similar in these 2 patients, Patient A had a vertebral fracture and indices were suggestive of fewer trabecular plates and higher erosion index compared to patient B.
Figure 3.
Bone mineral density T-scores of the spine, hip and HR-MRI indices including BV/TV (%), surface density, surface/curve ratio and erosion index in patient A with a vertebral fracture and patient B without a vertebral fracture. Surface density x10−2, Erosion index × 10−1.
DISCUSSION
We found that 37% of men with prostate cancer on androgen deprivation therapy had vertebral fractures and the majority were silent. Furthermore, DXA assessed bone mineral density measurements alone using the standard of care assessment of spine and hip measurements only would lead to misclassification of osteoporosis of approximately 90% of patients. We observed that men with vertebral fractures had a lower surface density suggestive of fewer trabecular plates and a higher erosion index, compared to men without fracture.
Previous studies have examined the importance of examining trabecular microstructure in the assessment of skeletal integrity. Wehrli and colleagues examined 79 women ages 28–78 years (mean age 54) with a HR-MRI of the forearm in addition to conventional vertebral fractures 17. They observed that there was no significant difference in standard DXA of the spine, femoral neck or trochanter between women with a vertebral fracture and those without. However, they reported significant difference in the radial HR-MRI indices between those with a vertebral fracture and those without. They reported that those with vertebral deformities had a lower ratio of plate-like to rod-like trabeculae to those without vertebral deformity. The number of intact trabecular rods were also lower in the vertebral deformity group. Our current study supports this information, but in a cohort of men at risk for osteoporosis who are on androgen deprivation therapy. Furthermore, by ROC analysis, the addition of the HR-MRI indices to conventional DXA T-scores of the hip and spine added substantially to the prediction of moderate-severe VF.
We observed weak to moderate correlations between the HR-MRI indices and measures of DXA at spine and hip sites, in addition to the forearm. The site with the strongest correlation, the ultra distal radius, was the site where the coil was placed. Furthermore, longer duration of ADT was negatively associated with the HR-MRI indices but not the conventional measures of DXA assessed BMD at the spine or hip. The spine may be falsely elevated due to osteoporotic calcifications and even the hip site may be falsely elevated due to osteoarthritis. The site with the strongest association with duration of ADT was the 1/3 distal radius. We have previously demonstrated that this site may be more sensitive to loss in men on androgen deprivation therapy 21;27. Because HR-MRI provides information on micro-structure and connectivity not available by conventional DXA, studies are needed to determine if HR-MRI in conjunction with DXA are useful in predicting future fractures.
Earlier investigations in men with prostate cancer on ADT have reported a range from 24% to 53% prevalence for DXA classification of osteoporosis28–30. Most investigations classify osteoporosis utilizing the World Health Classification of a bone mineral density ≤−2.5 SD below peak bone mass 31. However, the classification may vary depending on the number of skeletal sites used to meet the classification (eg. spine, total hip, femoral neck, 1/3 distal radius with combinations of 2–4 sites), the reference database (NHANES32, local comparison, gender, race), the study design (chart review, cross-sectional, clinical trial), patient age, duration of ADT and inclusion criteria. Our study found a prevalence of 7% for osteoporosis with the conventional DXA of the spine, total hip and femoral neck only, but this increased to 27% when we included the 1/3 distal radius. Adler and colleagues reported a prevalence of 33% in men with prostate cancer on ADT when he included the spine, hip and forearm as well 29. The prevalence of osteoporosis by DXA of 4 distinct sections of the hip using the U.S. NHANES male database was 3–6% 32. Therefore the prevalence differs depending on the number and location of skeletal sites included.
Moreover, there is variation in the radiologic definition of a vertebral fracture. Studies may classify vertebral fractures by DXA-derived vertebral fracture assessment or conventional lateral, thoracic lumbar x-rays. Vertebral fractures may be classified based on semi-quantitative, quantitative morphometric 22, algorithm-based qualitative analysis 33, clinical reading by a site radiologist or unspecified criteria. In community dwelling men participating in the Osteoporotic Fractures in Men (MrOS) study, the prevalence of vertebral fractures ranged from 10 to 13 % based on 3 conventional techniques, with moderate agreement (kappa = 0.42–0.62) but up to 74% of men had at least 1 vertebrae with short vertebral height that is often confused with a vertebral fracture 34. Other investigators report a prevalence range of 12–20% in men 35. For the present study we used vertebral fracture assessment and conventional thoracic/lumbar x-rays using the Genant method of semi-quantitative analysis, read by a single radiologist with expertise in skeletal radiology and reported a prevalence of 37%. The prevalence values for both DXA classified osteoporosis and vertebral fractures need to be viewed in the context of multiple ascertainment techniques and differences in analysis.
As expected, the 10 year risk of a major osteoporotic fracture or hip fracture using FRAX were higher in men with moderate-severe VF compared to lesser grades. However there are limitations with FRAX. Although we calculated FRAX for all men, FRAX was designed to include men with low femoral neck bone mass or osteopenia rather than osteoporosis. Men with clinical osteoporosis by VF would be treated regardless of FRAX score. Furthermore, FRAX wouldn’t include those with osteoporosis in the spine or forearm DXA, who would be treated.
We found that on average the total daily calcium intakes were above the current Institute of Medicine (IOM) and National Osteoporosis Foundation recommendations of 1200 mg/d and calcium intake was the highest in men with mod-severe VF. In addition the mean intake of vitamin D was near the IOM recommendations of 800 IU/d in those with no fracture and above 800 IU/d for those with fractures. Moreover, mean vitamin D levels were above the 20 ng/dL levels in all groups. Men with prostate cancer on ADT have been encouraged to meet these standards in clinical guidelines 36. Finally we found that although CTx, the marker of bone resorption, was higher in men with most severe VF, P1NP, a marker of bone formation, was similar among the 3 groups.
We included 2 patients with relatively similar assessments for conventional DXA measures at the hip and spine and with T-scores that would have classified both with a “normal” BMD. However, 1 patient had a vertebral fracture not assessed by conventional DXA, and the HR-MRI highlighted the loss of trabecular structure not seen with standard DXA or x-rays. These type of assessments may lead to future studies to determine if therapeutic alternatives should be based on structure in addition to overall bone mass.
Our study had several limitations. First, we only examined men age 60 and older with prostate cancer on ADT, and results may not necessarily apply to men in general or younger men with prostate cancer on ADT. Second, our cohort was predominantly Caucasian and the results may not necessarily apply to minorities. Third, we examined height loss assessed by memory of a participant’s tallest height; however, there may be recall bias in using this method. Finally, the cross-sectional associations found in our analyses do not carry the same level of strength in evidence as a longitudinal prediction of future fractures with an independent validation cohort.
This study also has several strengths. We were able to assess conventional bone mineral density, conventional lateral spine x-rays, forearm bone mineral density, biochemical markers of bone turnover and HR-MRI simultaneously in men with prostate cancer on ADT. Second, we were able to examine the impact of duration of therapy on these variables by including men who had been on ADT for a variable length of time. Third, we confirmed all x-rays assessed by vertebral fracture assessment with the conventional lateral x-rays using a single radiologist.
We conclude that vertebral fractures are found in 37% of men with prostate cancer on ADT. DXA based criteria alone will under diagnose and misclassify patients. HR-MRI provides a novel technique to assess the deterioration of micro-structural integrity in men with prostate cancer on ADT with vertebral fractures and adds additional information to conventional bone mineral density and vertebral fracture assessment.
Acknowledgments
PC060710 (DOD IDEA), 2K24DK062895-06, University of Pittsburgh Clinical Translational Research Center RFA-RM-06-002, University of Pittsburgh Dept of Urology, Claude D. Pepper Center, Division of Geriatric Medicine 2 P30 AG024827-06.
Footnotes
Author’s role: Study design: SLG, SP, JBN, NMR; Study conduct: SLG, JW; Data collection: SLG, JW, CB; Data analysis: SP; Data interpretation: SLG, SP, JBN, NMR, CB; Drafting manuscript: SLG, SP, NMR; Revising manuscript: SLG, SP; Approval of final version of manuscript: SLG, SP, JW, JBN, NMR, CB. The authors take responsibility for the integrity and accuracy of the data analysis.
Reference List
- 1.Catalona W. Management of cancer of the prostate. N Engl J Med. 1994;331:996–1004. doi: 10.1056/NEJM199410133311507. [DOI] [PubMed] [Google Scholar]
- 2.Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Can Inst. 2003;95:981–9. doi: 10.1093/jnci/95.13.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171–6. doi: 10.1016/j.urology.2004.07.037. [DOI] [PubMed] [Google Scholar]
- 4.Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64. doi: 10.1056/NEJMoa041943. [DOI] [PubMed] [Google Scholar]
- 5.Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541–9. doi: 10.1002/cncr.20388. [DOI] [PubMed] [Google Scholar]
- 6.Townsend MF, Sanders WH, Northway RO, Graham SDJ. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer. 1997;79:545–50. doi: 10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- 7.Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86:449–52. doi: 10.1046/j.1464-410x.2000.00774.x. [DOI] [PubMed] [Google Scholar]
- 8.Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–8. doi: 10.1016/s0022-5347(05)65661-3. [DOI] [PubMed] [Google Scholar]
- 9.Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128(10):793–800. doi: 10.7326/0003-4819-128-10-199805150-00001. [DOI] [PubMed] [Google Scholar]
- 10.Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc. 2000;48:241–9. doi: 10.1111/j.1532-5415.2000.tb02641.x. [DOI] [PubMed] [Google Scholar]
- 11.Bouxsein ML. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin Cornerstone. 2003;2:13–21. doi: 10.1016/s1098-3597(03)90043-3. [DOI] [PubMed] [Google Scholar]
- 12.Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586–92. doi: 10.1210/jcem.87.4.8415. [DOI] [PubMed] [Google Scholar]
- 13.Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–9. doi: 10.1016/s0002-9343(01)01124-x. [DOI] [PubMed] [Google Scholar]
- 14.Sullivan S, Wagner J, Resnick NM, Nelson J, Perera S, Greenspan SL. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom. 2011 doi: 10.1016/j.jocd.2011.05.003. In press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Borah B, Dufresne E, Chmielwski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736–46. doi: 10.1016/j.bone.2003.12.013. [DOI] [PubMed] [Google Scholar]
- 16.Wehrli FW, Saha PK, Gomberg BR, Song HK, Snyder PJ, Benito M, et al. Role of magnetic resonance for assessing structure and function of trabecular bone. Top Magn Reson Imaging. 2002;13(5):335–56. doi: 10.1097/00002142-200210000-00005. [DOI] [PubMed] [Google Scholar]
- 17.Wehrli FW, Gomberg BR, Saha PK, Song HK, Hwang SN, Snyder PJ. Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J Bone Miner Res. 2001;16:1520–31. doi: 10.1359/jbmr.2001.16.8.1520. [DOI] [PubMed] [Google Scholar]
- 18.Wehrli FW. Structural and functional assessment of trabecular and cortical bone by micro magnetic resonance imaging. J Magn Reson Imaging. 2007;25:390–409. doi: 10.1002/jmri.20807. [DOI] [PubMed] [Google Scholar]
- 19.Greenspan SL, Perera S, Recker R, Wagner JM, Greeley P, Gomberg BR, et al. Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy. Bone. 2009;46(4):1006–10. doi: 10.1016/j.bone.2009.12.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kanis JA for the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368–81. doi: 10.1007/BF01622200. [DOI] [PubMed] [Google Scholar]
- 21.Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, et al. Skeletal Health Following Continuation, Withdrawal or Delay of Alendronate in Men with Prostate Cancer on Androgen Deprivation Therapy. J Clin Oncol. 2008;26:4426–34. doi: 10.1200/JCO.2007.15.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–48. doi: 10.1002/jbmr.5650080915. [DOI] [PubMed] [Google Scholar]
- 23.Kanis JA, Bianchi G, Bilezikian JP, Kaufman J-M, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789–98. doi: 10.1007/s00198-011-1632-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wehrli FW, Hwang SN, Ma J, Song HK, Ford JC, Haddad JG. Cancellous bone volume and structure in the forearm: noninvasive assessment with MR microimaging and image processing. Radiology. 1998;206:347–57. doi: 10.1148/radiology.206.2.9457185. [DOI] [PubMed] [Google Scholar]
- 25.Gomberg BR, Wehrli FW, Vasilic B, Weening RH, Saha PK, Song HK, et al. Reproducibility and error sources of Micro-MRI-based trabecular bone structural parameters of the distal radius and tibia. Bone. 2004;35:266–76. doi: 10.1016/j.bone.2004.02.017. [DOI] [PubMed] [Google Scholar]
- 26.Apfel CC, Kranke P, Greim CA, Roewer N. What can be expected from risk scores for predicting postoperative nausea and vomiting? Br J Anaesth. 2001;86(6):822–7. doi: 10.1093/bja/86.6.822. [DOI] [PubMed] [Google Scholar]
- 27.Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410–7. doi: 10.1210/jc.2005-0183. [DOI] [PubMed] [Google Scholar]
- 28.Bruder JM, Ma J, Basler JW, Welch MD. Prevelence of osteopenia and osteoporosis by central and peripeheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology. 2006;67:152–5. doi: 10.1016/j.urology.2005.07.017. [DOI] [PubMed] [Google Scholar]
- 29.Adler RA, Hastings FW, Petkov VI. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int. 2010;21:647–53. doi: 10.1007/s00198-009-0984-0. [DOI] [PubMed] [Google Scholar]
- 30.Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urology. 2011;186:482–6. doi: 10.1016/j.juro.2011.03.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level. University of Sheffield; UK: WHO Collaborating Center; 2008. [Google Scholar]
- 32.Looker AC, Orwoll ES, Johnston CC, Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12(11):1761–8. doi: 10.1359/jbmr.1997.12.11.1761. [DOI] [PubMed] [Google Scholar]
- 33.Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P. A new approach to defining normal vertebral dimensions. J Bone Miner Res. 1991;6(8):883–92. doi: 10.1002/jbmr.5650060814. [DOI] [PubMed] [Google Scholar]
- 34.Ferrar L, Jiang G, Cawthon PM, Valentin RS, Fullman R, Lambert L, et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: The MrOS Study. J Bone Miner Res. 2007;22:1434–41. doi: 10.1359/jbmr.070608. [DOI] [PubMed] [Google Scholar]
- 35.Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441–64. doi: 10.1210/er.2008-0002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab. 2008;93(1):2–7. doi: 10.1210/jc.2007-1402. [DOI] [PMC free article] [PubMed] [Google Scholar]

